The proliferative component of chronic myelomonocytic leukemia, related to an increased sensitivity of myeloid progenitors to granulocyte macrophage–colony stimulating factor, suggests dedicated therapeutic approaches. In this issue, ruxolitinib, a JAK1 and -2 inhibitory drug, is shown to induce objective responses in chronic myelomonocytic leukemia patients. Clin Cancer Res; 22(15); 3707–9. ©2016 AACR.
See related article by Padron et al., p. 3746
from Cancer via ola Kala on Inoreader http://ift.tt/2aoSco2
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου